A novel bromodomain BRD4 inhibitor that significantly induces HIV-1 reactivation.

A novel brain penetrant antiprion compound with EC50 of 57 nM, prevents both PrP(Sc) accumulation and astrocytic gliosis in the cerebrum.

A novel bifunctional PDE4 inhibitor (IC50=5 nM) and long acting β2-adrenoceptor agonist (EC50=8 nM).

A novel anti-TB agent that has an MIC range of 0.06-0.5 ug/mL..

A novel antiprion compound with EC50 of 68 nM, significantly increases monoglycosylated/diglycosylated PrPSc..

A novel antifolate modulator compound..

A novel and irreversible inhibitor of mutant K-ras G12C..

A novel and irreversible inhibitor of mutant K-ras G12C..

A novel and irreversible inhibitor of mutant K-ras G12C..

A novel and highly selective 5-HT6 receptor small molecule antagonist with Ki of 2.34 nM.

A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.

A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.

A novel a potent, selective inhibitor of BRD4 with Kd of 550 nM, cellular IC50 of 724 nM.

A novel 5-HT receptor antagonist for the treatment of Parkinson's disease..

A nove potent, selective and reversible SHP2 inhibitor with Ki of 0.51 uM.

A nove potent, dual FGFR and PIK3C3 inhibitor with Kd of 0.53 nM for PIK3C3.

A nootropic agent that enhances high-affinity choline uptake.

A non-steroidal sulphamate analogue of 2-methoxyoestradiol (2ME2) and microtubule disruptor, shows anti-proliferative activity against NCI 60 cell lines with mean GI50 of 50 nM.

A nonsteroidal selective estrogen receptor modulator (SERM) that shows 10- to 60-fold increased affinity for the estrogen receptor compared with Tamoxifen.

A non-steroidal anti-inflammatory drug (NSAID).

A nonselective inhibitor of UBL protein-activating E1 enzymes that forms covalent adducts with UBL proteins SUMO1, ubiquitin, Nedd8, ISG15, and GABARAP in the presence of ATP and E1 enzymes in vitro.

A non-selective beta blocker used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent..

A non-selective agonist of the dopamine D3 receptor (Ki=0.71 nM).

A non-selective agonist of Adenosine A3 receptor.

A non-planar analogue of fascaplysin that selectively inhibits CDK4/cyclin D1 with IC50 of 5.5 uM.

A nonpeptidyl small molecule agonist of GDNF family receptor α1 (GFRα-1).

A nonpeptidic, selective, brain-penetrant agonist of nociceptin/orphanin FQ receptor (NOP receptor/ORL1) with pKi of 9.41.

A non-peptide, selective RGS4 inhibitor that inhibits RGS4/Gα(o) binding with 3 to 5 uM potency.

A nonpeptide, cell-permeable STAT3 inhibitor that binds directly to the pTyr705 binding site of the STAT3 monomer.

A nonnucleoside, competitive, small-molecule inhibitor of human ribonucleotide reductase (hRR) that binds to the large subunit hRRM1 at the catalytic site (C-site) with Kd of 37.4 uM, IC50 of 32 uM.